X-ZELL selected as Finalist for 2020 Hello Tomorrow Global Challenge
Singapore, January 2020 – Singapore med tech start-up, X-ZELL, has been nominated as a Global Finalist for the 2020 Hello Tomorrow Challenge.
Considered one of the world’s leading deep tech start-up competitions, the Challenge was created to celebrate the “best and brightest breakthrough solutions” made possible by science and technology.
According to Hello Tomorrow’s organising committee, it received a record-breaking 5,000 applications from 128 countries for the 2020 instalment of the event.
X-ZELL is one of 80 finalists selected for demonstrating the potential to “radically transform the way we live, move, eat, power and run our industries”, and one of only six remaining organisations in the ‘Medical Biotech’ category.
“We are extremely humbled to have been selected as a Hello Tomorrow Global Challenge Finalist in the highly competitive Medical Biotech track, and we can’t wait to share our work with the world at the Paris Summit,” commented Dr Sebastian Bhakdi, Founder & CEO of X-ZELL.
“Rooted in a strong scientific foundation and supported by a passionate, globally accomplished team, I truly believe X-ZELL has the potential to make the proverbial dent in the universe.”
In Paris, Dr Bhakdi will be presenting a three-minute pitch to a jury of internationally acclaimed investors, industry experts, entrepreneurs and journalists, who will evaluate X-ZELL on four key criteria – technological innovation, impact, economic viability and team.
In the lead-up to the highly anticipated event, X-ZELL’s ground-breaking early cancer detection technology has also been recognised as one of the 750 most promising deep tech projects in the world, earning it the status of a global Deep Tech Pioneer.
The global Hello Tomorrow Challenge Finale will be held in Paris, France from 10-13 March 2020.
Date: 10-13 Mar 2020
Venue: The Centquatre, Paris, FRA
Head of Strategy, Marketing & Communications
+65 9630 0706
Recurrently ranked among the most innovative health technology start-ups in Asia, X-ZELL is fusing next-generation cell detection technology with cutting-edge Artificial Intelligence to isolate and visualise ultra-rare cells in blood and frozen tissue. Established in Bangkok, Thailand, the company recently made global headlines when it demonstrated the ability to routinely locate tumour-associated Circulating Endothelial Cells (tCEC) in small, 10mL blood samples. Widely considered one of the most promising biomarkers for the early detection of clinically significant cancers, tCEC had previously been classified as undetectable in clinical routine. Now headquartered in Singapore, X-ZELL is aiming to make tCEC-based cancer screening accessible to patients around the globe – making the young company one of the promising names in the booming cancer prevention space.
About Hello Tomorrow
Hello Tomorrow is a global non-profit on a mission to accelerate deep technology research and entrepreneurship, and to bring breakthrough innovation to commercial scale. Headquartered in Paris, France, the organisation can draw on a network of six regional hubs around the world as well as a global grassroots community. The Hello Tomorrow Global Challenge is considered the largest deep-tech start-up competition in the world.